| Literature DB >> 30308071 |
Charlie Tan1, Mark S Hansen2, Gideon Cohen3, Karl Boyle4, Alvin Yang5, Asgar Rishu6, Ruxandra Pinto6, Neill K J Adhikari7,8, Nick Daneman9,10,11.
Abstract
BACKGROUND: A multidisciplinary approach has been recommended for the management of patients with infective endocarditis. We evaluated the impact of multidisciplinary case conferences on morbidity, mortality, and quality of care for these patients.Entities:
Mesh:
Year: 2018 PMID: 30308071 PMCID: PMC6181397 DOI: 10.1371/journal.pone.0205528
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics, microbiologic etiology and endocardial involvement of pre-intervention and post-intervention groups.
| Characteristic (%) | Overall (p = 177) | Pre-intervention | Post-intervention | p value |
|---|---|---|---|---|
| Mean age, in years (standard deviation) | 65.0 (17.6) | 65.4 (19.2) | 64.5 (15.5) | 0.74 |
| Male | 124 (70.1) | 66 (68.0) | 58 (72.5) | 0.62 |
| Route of admission | ||||
| Direct | 109 (61.6) | 61 (62.9) | 48 (60.0) | 0.76 |
| Transfer | 68 (38.4) | 36 (37.1) | 32 (40.0) | |
| Definite | 125 (70.6) | 69 (71.1) | 56 (70.0) | 0.87 |
| Probable | 52 (29.4) | 28 (28.9) | 24 (30.0) | |
| Coronary artery disease | 43 (24.3) | 26 (26.8) | 17 (21.3) | 0.48 |
| Coronary artery bypass grafting | 19 (10.7) | 11 (11.3) | 8 (10.0) | 0.81 |
| Prosthetic valve(s) | 57 (32.2) | 32 (33.0) | 25 (31.3) | 0.87 |
| Unrepaired valve lesion | 36 (20.3) | 23 (23.7) | 13 (16.3) | 0.63 |
| Intracardiac device | 23 (13.0) | 12 (12.4) | 11 (13.8) | 0.83 |
| Prior infective endocarditis | 22 (12.4) | 12 (12.4) | 10 (12.5) | 1 |
| Intravenous drug use | 14 (7.9) | 8 (8.2) | 6 (7.5) | 1 |
| Intravenous instrumentation (hemodialysis, central venous line) | 8 (4.5) | 4 (4.1) | 4 (5.0) | 1 |
| Hypertension | 92 (52.0) | 49 (50.5) | 43 (53.8) | 0.76 |
| Diabetes mellitus | 46 (26.0) | 22 (22.7) | 24 (30.0) | 0.30 |
| Cerebrovascular disease | 32 (18.1) | 20 (20.6) | 12 (15.0) | 0.43 |
| Chronic obstructive pulmonary disease | 9 (5.1) | 8 (8.2) | 1 (1.3) | |
| Chronic kidney disease | 34 (19.2) | 17 (17.5) | 17 (21.3) | 0.57 |
| Liver disease | 14 (7.9) | 8 (8.2) | 6 (7.5) | 1 |
| Malignancy | 41 (23.2) | 27 (27.8) | 14 (17.5) | 0.11 |
| Heart failure | 59 (33.3) | 38 (39.2) | 21 (26.3) | 0.08 |
| Neurologic emboli | 37 (20.9) | 20 (20.6) | 17 (21.3) | 1 |
| Non-neurologic emboli | 46 (26.0) | 21 (21.6) | 25 (31.3) | 0.17 |
| Mycotic aneurysm | 4 (2.3) | 3 (3.1) | 1 (1.3) | 0.63 |
| 45 (25.4) | 21 (21.6) | 24 (30.0) | 0.23 | |
| Viridans group streptococci | 47 (26.6) | 27 (27.8) | 20 (25.0) | 0.73 |
| 29 (16.4) | 16 (16.5) | 13 (16.3) | 1 | |
| HACEK group species | 4 (2.3) | 2 (2.1) | 2 (2.5) | 1 |
| Coagulase-negative staphylococci | 10 (5.6) | 6 (6.2) | 4 (5.0) | 1 |
| Other microorganism | 32 (18.1) | 22 (22.7) | 10 (12.5) | 0.12 |
| Culture-negative endocarditis | 13 (7.3) | 8 (8.2) | 5 (6.3) | 0.77 |
| Valves or devices affected | ||||
| Native mitral valve | 66 (37.3) | 34 (35.1) | 32 (40.0) | 0.53 |
| Native aortic valve | 51 (28.8) | 29 (29.9) | 22 (27.5) | 0.74 |
| Native tricuspid valve | 14 (7.9) | 9 (9.3) | 5 (6.3) | 0.58 |
| Native pulmonic valve | 2 (1.1) | 2 (2.1) | 0 (0) | 0.50 |
| Prosthetic mitral valve | 10 (5.6) | 3 (3.1) | 7 (8.8) | 0.19 |
| Prosthetic aortic valve | 21 (11.9) | 10 (10.3) | 11 (13.8) | 0.49 |
| Other prosthetic valve, conduit or shunt | 0 (0) | 0 (0) | 0 (0) | 1 |
| Intracardiac device | 7 (4.0) | 1 (1.0) | 6 (7.5) | |
| Multiple valves involved | 25 (14.1) | 10 (10.3) | 15 (18.8) | 0.13 |
| No definite echocardiographic evidence of endocardial involvement | 39 (22.0) | 23 (23.7) | 16 (20.0) | 0.59 |
| Mean maximum vegetation diameter, in cm (standard deviation) | 1.41 (0.83) | 1.29 (0.67) | 1.52 (0.96) | 0.18 |
| Vegetation hypermobility | 59 (33.3) | 27 (27.8) | 32 (40.0) | 0.11 |
| Valve disruption or perforation | 60 (33.9) | 32 (33.0) | 28 (35.0) | 0.87 |
| Abscess | 23 (13.0) | 11 (11.3) | 12 (15.0) | 0.51 |
| Fistula | 2 (1.1) | 0 (0) | 2 (2.5) | 0.20 |
*Patients with documented vegetation diameters on echocardiography (pre-intervention: n = 50, post-intervention: n = 48)
HACEK = Haemophilus spp., Aggregatibacter actinomycetemcomitans, Aggregatibacter aphrophilus, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae
Protocol adherence process measures in post-intervention group.
| Outcome (%) | Post-intervention |
|---|---|
| Working group discussion | 80 (100) |
| Electronic | 49 (61.3) |
| Face-to-face case conference | 31 (38.8) |
| Median time from admission to case conference, in days (interquartile range) | 4 (2–7) |
| Recommendation made | |
| Emergent surgery | 4 (5.0) |
| Urgent surgery | 19 (23.8) |
| Elective surgery, prior to discharge | 2 (2.5) |
| Elective surgery, after discharge | 2 (2.5) |
| Surgery decision pending, re-assess in hospital | 2 (2.5) |
| Surgery decision pending, re-assess after discharge | 1 (1.3) |
| Medical management | 46 (57.5) |
| Recommendation entered into electronic medical record | 55 (68.8) |
Hospital care process measures of pre-intervention and post-intervention groups.
| Outcome (%) | Pre-intervention | Post-intervention | p value |
|---|---|---|---|
| Assessments performed | |||
| Cardiac surgery | 57 (58.8) | 39 (48.8) | 0.22 |
| Cardiology | 62 (63.9) | 65 (81.3) | |
| Infectious diseases | 97 (100) | 79 (98.8) | 0.45 |
| Cardiac surgery performed | 21 (21.6) | 28 (35.0) | 0.06 |
| Median time from admission to surgery, in days (interquartile range) | 8 (5–14) | 6.5 (3.75–11.25) | 0.43 |
| Appropriate antimicrobial agent | 97 (100) | 80 (100) | 1 |
| Appropriate antimicrobial duration | 97 (100) | 80 (100) | 1 |
| Follow-up | |||
| Cardiac surgery | 16 (19.3) | 18 (28.1) | 0.24 |
| Cardiology | 17 (20.5) | 21 (32.8) | 0.13 |
| Infectious diseases | 53 (63.9) | 38 (59.4) | 0.61 |
*Excluding hospital deaths (pre-intervention: n = 83, post-intervention: n = 64)
Patient outcomes in pre-intervention and post-intervention groups.
| Outcome | Pre-intervention | Post-intervention | p value |
|---|---|---|---|
| Complications new or worse from admission (%) | |||
| Any complication | 50 (51.5) | 32 (40.0) | 0.13 |
| Congestive heart failure | 19 (19.6) | 9 (11.3) | 0.15 |
| Ischemic stroke | 7 (7.2) | 4 (5.0) | 0.76 |
| Hemorrhagic stroke | 7 (7.2) | 2 (2.5) | 0.19 |
| Non-neurologic emboli | 7 (7.2) | 4 (5) | 0.76 |
| Mycotic aneurysm | 0 (0) | 2 (2.5) | 0.20 |
| Arrhythmia | 23 (23.7) | 14 (17.5) | 0.36 |
| Unexpected or prolonged critical care admission | 23 (23.7) | 10 (12.5) | 0.08 |
| Intra-aortic balloon pump | 0 (0) | 1 (1.3) | 0.45 |
| Renal replacement therapy | 6 (6.2) | 11 (13.8) | 0.12 |
| Median length of hospital stay, in days (interquartile range) | 14 (9–26) | 13.5 (7–21.25) | 0.20 |
| Loss to follow-up | 8 (8.2) | 2 (2.5) | 0.12 |
| Re-admissions (%) | 24 (31.6) | 17 (28.3) | 0.71 |
| Attributable re-admissions | 20 (26.3) | 8 (13.3) | 0.09 |
| Relapses (%) | 3 (3.9) | 1 (1.7) | 0.63 |
| Hospital mortality (%) | 13 (13.4) | 18 (22.5) | 0.16 |
| Mortality up to 90 days after hospital discharge (%) | 17 (17.5) | 21 (26.3) | 0.20 |
*Excluding losses to follow-up and patients who died during the index hospitalization (pre-intervention: n = 76, post-intervention: n = 60)
Results of multivariable logistic regression for effect of the case conferencing intervention on mortality up to 90 days after hospital discharge and a composite of mortality and development of new or worse complications.
| Variable | Mortality up to 90 days after hospital discharge | Composite of mortality and new or worse complications | ||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Intervention | 1.87 (0.88–3.99) | 0.10 | 0.86 (0.46–1.58) | 0.63 |
| Age | 1.01 (0.99–1.04) | 0.25 | 0.99 (0.97–1.01) | 0.29 |
| 2.10 (0.92–4.81) | 0.08 | 1.44 (0.71–2.93) | 0.31 | |
| Heart failure | 2.32 (1.06–5.08) | 1.24 (0.65–2.35) | 0.52 | |
CI = confidence interval, OR = odds ratio